{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Transduced+Autologous+CD34%2B+Stem+Cells&page=2",
    "query": {
      "intervention": "Gene-Transduced Autologous CD34+ Stem Cells",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 36,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Transduced+Autologous+CD34%2B+Stem+Cells&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gene-Transduced+Autologous+CD34%2B+Stem+Cells&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T04:38:09.558Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003567",
      "title": "Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic autologous lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "O6-benzylguanine",
          "type": "DRUG"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "1999-05",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003567"
    },
    {
      "nct_id": "NCT00569985",
      "title": "Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carmustine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "autologous hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 5,
      "start_date": "2007-06",
      "completion_date": "2019-11-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00569985"
    },
    {
      "nct_id": "NCT01896102",
      "title": "A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cerebral Adrenoleukodystrophy (CALD)"
      ],
      "interventions": [
        {
          "name": "Lenti-D Drug Product (eli-cel)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "Up to 17 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2013-08-21",
      "completion_date": "2021-03-26",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896102"
    },
    {
      "nct_id": "NCT04105166",
      "title": "Gene Therapy for Pyruvate Kinase Deficiency (PKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pyruvate Kinase Deficiency"
      ],
      "interventions": [
        {
          "name": "RP-L301",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rocket Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "8 Years to 50 Years"
      },
      "enrollment_count": 4,
      "start_date": "2020-07-06",
      "completion_date": "2025-06-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04105166"
    },
    {
      "nct_id": "NCT01512888",
      "title": "Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Severe Combined Immunodeficiency Disease, X-linked"
      ],
      "interventions": [
        {
          "name": "CL20-i4-EF1α-hγc-OPT",
          "type": "GENETIC"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "CliniMacs",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "MALE",
        "summary": "Up to 24 Months · Male only"
      },
      "enrollment_count": 28,
      "start_date": "2016-08-17",
      "completion_date": "2034-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Memphis, Tennessee • Seattle, Washington",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01512888"
    },
    {
      "nct_id": "NCT02906202",
      "title": "A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "LentiGlobin BB305 Drug Product",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2016-08-08",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02906202"
    },
    {
      "nct_id": "NCT01177059",
      "title": "Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "OZ1 transduced cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Janssen-Cilag Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 68,
      "start_date": "2004-12-06",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • San Francisco, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177059"
    },
    {
      "nct_id": "NCT01852071",
      "title": "Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ADA-SCID"
      ],
      "interventions": [
        {
          "name": "Infusion of autologous EFS-ADA LV CD34+ (OTL-101)",
          "type": "GENETIC"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "PEG-ADA ERT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 46,
      "start_date": "2013-08-02",
      "completion_date": "2018-08-27",
      "has_results": true,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Bethesda, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852071"
    },
    {
      "nct_id": "NCT03207009",
      "title": "A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "LentiGlobin BB305 Drug Product",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Genetix Biotherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "0 Years to 50 Years"
      },
      "enrollment_count": 19,
      "start_date": "2017-06-08",
      "completion_date": "2022-11-15",
      "has_results": true,
      "last_update_posted_date": "2024-03-07",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Chicago, Illinois • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207009"
    },
    {
      "nct_id": "NCT03897361",
      "title": "Stem Cell Gene Therapy for Cystinosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lysosomal Storage Diseases",
        "Cystinosis"
      ],
      "interventions": [
        {
          "name": "CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-07-08",
      "completion_date": "2024-09-18",
      "has_results": true,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-09T04:38:09.558Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03897361"
    }
  ]
}